Cyxone Second Quarter 2024 Earnings: kr0.02 loss per share (vs kr0.045 loss in 2Q 2023)

Cyxone (STO:CYXO) Second Quarter 2024 Results

Key Financial Results

• Net loss: kr4.75m (loss widened by 12% from 2Q 2023).
• kr0.02 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cyxone Earnings Insights

Looking ahead, revenue is expected to decline by 122% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Sweden are expected to grow by 18%.

Performance of the Swedish Biotechs industry.

The company's shares are up 11% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Cyxone has 6 warning signs (and 5 which shouldn't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.